郑应馨　 徐恒卫　 项宇峰　 舒心　

关键词：抗肿瘤药物;药物代谢酶;合理用药
分类号：R979.1　文献标识码：A
文章编号：1008-049X(2006)05-0466-03
 

　　肿瘤是严重威胁人类健康的常见病和多发病.目前肿瘤的治疗仍然是以化疗、放疗、手术治疗为主,其中化疗仍然是治疗肿瘤的主要手段之一,但是在肿瘤的药物化疗过程中,常能见到相同病症的不同病人对同一种抗肿瘤药物出现不同的反应,有的甚至血药浓度相同,但是疗效大相径庭.近年来,随着分子生物学、分子遗传学与分子药理学的发展,人们逐渐认识到,不同个体对同一抗肿瘤药物的不同反应,很多是源于抗肿瘤药物相关代谢酶的活性在个体间的差异,如:细胞色素P450酶3A4(CYP3A4)活性在个体间的差异可达30倍;硫嘌呤甲基转移酶(TPMT)活性在个体间的差异大于30倍;尿苷二磷酸-葡萄糖醛酸转移酶(UGT)活性在个体间的差异可达50倍.因此,在临床肿瘤化疗过程中,要重视抗肿瘤药物相关代谢酶的个体差异,在有条件的医院可以开展酶表型与基因型的测定工作,并且注意其它合用药物对酶的诱导与抑制.这样才能为抗肿瘤药物的合理应用提供强有力的保证.……
 
作者简介：郑应馨,男,研究员,硕士,主要从事肿瘤的药物治疗研究.Tel:(0531)7984777-82285 E-mail:xuhengwei2001@yahoo.com.cn
作者单位：郑应馨（山东省肿瘤医院药剂科,济南,250117）　
　　　　　徐恒卫（山东省肿瘤医院药剂科,济南,250117）　
　　　　　项宇峰（山东省肿瘤医院药剂科,济南,250117）　
　　　　　舒心（山东省实验动物中心）　

参考文献：

[1]Gellner K,Eiselt R,Hustert E,et al.Genomic organization of the human CYP3A locus:identification of a new,inducible CYP3A gene[J].Pharmacogenetics,2001,11 (2):111-121
[2]Parkinson A,Mudra DR,Johnson C,et al.The effects of gender,age,ethnicity,and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes[J].Toxicol Appl Pharmacol,2004,199 (3):193-209
[3]MacLeod SL,Nowell S,Massengill J,et al.Cancer therapy and polymorphisms of cytochromes P450[J].Clin Chem Lab Med,2000,38(9):883-887
[4]Schwarz UI.Clinical relevance of genetic polymorphisms in the human CYP2C9gene[J].Eur J Clin Invest,2003,33 (Suppl 2):23-30
[5]Walsky RL,Obach RS,Gaman EA,et al.Selective inhibition of human cytochrome P4502C8 by montelukast[J].Drug Metab Dispos,2005,33 (3):413-418
[6]Yamaguchi K,Arai Y,Kanda Y,et al.Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil[J].Jpn J Cancer Res,2001,92(3):337-342
[7]McLeod HI,Krynetski EY,Relling MV,et al.Genetic polymorphism of thiopurine methyltransferase and its clinical rele-vance for childhood acute lymphoblastic leukemia[J].leukemia,2000,14 (4):567-572
[8]Evans WE,Hon YY,Bomgaars L,et al.Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine[J].J Clin Oncol,2001,19(8):2293-2301
[9]Zetterberg H.Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion:biological and clinical implications[J].Reprod Biol Endocrinol,2004,2(1):7
[10]Ando Y,Saka H,Ando M,el al.Polymorohisms of UDP-glucuronosyltransferase gene and irinotecan toxicity; a pharmacogenetic analysis[J].Cancer Res,2000,60(24):6921-6926
[11]Peters U,Preisler-Adams S,Hebeisen A,et al.Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin[J].Anticancer Drugs,2000,11 (8):639-643
[12]Lutz W.N-acetyltransferase genetic polymorphism and its role in the development of neoplastic disease[J].Med Pr,2000,51 (3):277-284
[13]Furet Y,Bechtel Y,Le Guellec C,et al.Clinical relevance of N-acetyltranserase type 2 (NAT2) genetic polymorphism[J].Therapie,2002,57 (5):427-431
[14]Niemi M,Backman JT,Neuvonen PJ.Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone[J].Clin Pharmacol Ther,2004,76 (3):239-249
[15]Hruska MW,Amico JA,Langaee TY,et al.The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects[J].Br J Clin Pharmacol,2005,59(1):70-79
[16]Walsky RL,Obach RS,Gaman EA,et al.Selective inhibition of human cytochrome P4502C8 by montelukast[J].Drug Metab Dispos,2005,33 (3):413-418
[17]Walsky RL,Gaman EA,Obach RS.Examination of 209 drugs for inhibition of cytochrome P4502C8[J].J Clin Pharmacol,2005,45(1):68-78
[18]Omura K.Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy:mutations in the DPD gene,and DPD inhibitory fluoropyrimidines[J].Int J Clin Oncol,2003,8(3):132-138
[19]Lennard L.Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interactions[J].Ther Drug Monit,1998,20(5):527-531
[20]Woodson LC,Ames MM,Selassie CD,et al.Thiopurine methyltransferase.Aromatic thiol substrates and inhibition by benzoic acid derivatives[J].Mol Pharmacol,1983,24(3):471-4.78
[21]Lucock MD,Wild J,Schorah CJ,et al.The methylfolate axis in neural tube defects:in vitro characterisation and clinical investigation[J].Biochem Med Metab Biol,1994,52(2):101-114
[22]Sakai-Kato K,Kato M,Toyo 'oka T.Screening of inhibitors of uridine diphosphate glucuronosyltransferase with a miniaturized on-line drug-metabolism system[J].J Chromatogr A,2004,1051 (1-2):261-266
[23]Uchida K.Induction of glutathione S-transferase by prostaglandins[J].Mech Ageing Dev,2000,116 (2-3):135-140
[24]Lu KH,Lin KL,Hsia TC,et al.Tamoxifen inhibits arylamine N-acetyltransferase activity and DNA-2-aminofluorene adduct in human leukemia HL-60cells[J].Res Commun Mol Pathol Pharmacol,2001,109(5-6):319-331
[25]Wang DY,Yeh CC,Lee JH,et al.Berberine inhibited arylamine N-acetyltransferase activity and gene expression and DNA adduct formation in human malignant astrocytoma (G9T/VGH) and brain glioblastoma multiforms (GBM 8401) cells[J].Neurochem Res,2002,27(9):883-889

 
收稿日期：2005年7月4日

出版日期：2006年5月5日